The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years, increasing from $3.99 billion in 2023 to $4.1 billion in 2024, at a compound annual growth rate (CAGR) of 2.7%. This growth in the historic period can be attributed to rising awareness and diagnosis of hormonal disorders, increasing prevalence of hormone-related diseases, a higher prevalence of prostate cancer, growing awareness about hormone therapy, and increased demand for long-term safety and efficacy. In the next few years, the gonadotropin-releasing hormone (GnRH) agonist market size is expected to continue this steady growth, reaching $4.6 billion in 2028 at a CAGR of 2.9%. This forecasted growth is driven by rising awareness and early diagnosis, increased healthcare expenditure, more frequent use in fertility treatments, growing demand for personalized medicine, and rising research funding and grants. Major trends during this period include advancements in drug delivery systems, progress in oncology and reproductive medicine, an increasing demand for hormone therapy options, more research and development activities, and a rise in long-acting formulations.

The rising prevalence of hormone-related diseases is anticipated to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders arise from imbalances or dysfunctions in the endocrine system, which regulates hormone production. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. The increasing incidence of hormone-related diseases is attributed to various factors, including environmental influences, obesity and metabolic syndrome, genetics, and an aging population. GnRH agonists are essential for effectively managing hormone levels and offer a tailored approach to treating issues associated with hormonal imbalances and related diseases. For instance, in June 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that there were 236,659 newly diagnosed cases of prostate cancer in the United States in 2021, and 33,363 men died from this disease in 2022. Consequently, the growing prevalence of hormone-related diseases is significantly contributing to the growth of the gonadotropin-releasing hormone (GnRH) agonist market through 2023, into 2024, and expectedly beyond to 2028.

Get A Free Sample On The Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18814&type=smp

What Are The Key Trends That Influence Gonadotropin-Releasing Hormone (GnRH) Agonist Market Share Analysis?

Major companies in the gonadotropin-releasing hormone (GnRH) agonist market are developing advanced androgen deprivation therapy drugs to enhance treatment effectiveness and precision for hormone-sensitive cancers. Androgen deprivation therapy (ADT) drugs, including GnRH analogs, work by reducing or eliminating androgen levels to slow or halt the growth of hormone-sensitive cancers. For instance, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Relugolix under the brand name Rexigo. It is India’s first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, removing the need for injectable treatments. This convenient oral option features Relugolix, a globally recognized active ingredient known for delivering rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable alternatives for advanced prostate cancer in India, marking a significant advancement in prostate cancer care and offering a safe, effective, and user-friendly treatment option for both patients and healthcare providers.

Which Market Players Are Driving Growth In The Gonadotropin-Releasing Hormone (GnRH) Agonist Market?

Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.

How Is The Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Segmented?

The gonadotropin-releasing hormone (GnRH) agonist market covered in this report is segmented –

1) By Type: Leuprorelin, Goserelin, Taltirelin, Histrelin, Other Types
2) By Formulation: Injectable, Implants, Oral, Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids, Precocious Puberty, Fertility Treatment, Other Applications
5) By End-User: Hospital, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Other End-Users

Read The Full Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report Here

https://www.thebusinessresearchcompany.com/report/gonadotropin-releasing-hormone-gnrh-agonist-global-market-report

The Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2024 provides an overview of the gonadotropin-releasing hormone (gnrh) agonistmarket for the time series: historic years (2010 – 2021) and ten years forecast (2023 – 2032). The gonadotropin-releasing hormone (gnrh) agonist market forecast analyzes gonadotropin-releasing hormone (gnrh) agonist market size, gonadotropin-releasing hormone (gnrh) agonist market share, leading competitor and their market positions.

The Table Of Content For The Gonadotropin-Releasing Hormone (GnRH) Agonist Market Include

1. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Executive Summary
2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Segments
3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Size And Template Market Growth Rate
4.  Key Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends
5. Major Gonadotropin-Releasing Hormone (GnRH) Agonist Market Drivers
……
25. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonist Market
26. Top Gonadotropin-Releasing Hormone (GnRH) Agonist Companies
27. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Opportunities And Strategies
28. Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Conclusions And Recommendations
29. Appendix

Explore Similar Reports From The Business Research Company:

Biosimilar Growth Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Tumor Embolization Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/sample_request?id=3432&type=smp

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model